Short term view - TONIX PHARMACEUTICALS HOLDING : The background trend is clearly bullish.
The background trend is clearly bullish. Prices are still making progress but there is less power in the movement.The next resistance is at $4.30. Breaking below the support at $3.50 would invalidate the trend.
Tonix Pharmaceuticals Holding is a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and to improve biodefense through the development of potential medical counter-measures. The company's main drug development program is focused on delivering a long-term treatment for posttraumatic stress disorder. The company's primary product candidate, Tonmya, or TNX-102 SL, is a proprietary low-dose cyclobenzaprine sublingual tablet, designed for bedtime administration. TNX-102 SL is also being developed as a treatment for agitation in Alzheimer's disease.
DayByDay is an independent research company providing global macro and single stock analysis, recommendation and allocation based purely on behavioural finance methods. Those include long term cycle analysis, sentiment analysis, and technical trigger. DayByDay serves all clients in need of practical and precise publications to make effective market decisions, on any time horizon, from a few hours to a few years.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.